Hakutulokset - Soon Hin How

  • Näytetään 1 - 5 yhteensä 5 tuloksesta
Tarkenna hakua
  1. 1
    Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding Pathogenesis

    Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding Pathogenesis Tekijä Sheila Nathan, Sylvia Chieng, Paul Vijay Kingsley, Anand Mohan, Yuwana Podin, Mong-How Ooi, Vanitha Mariappan, Kumutha Malar Vellasamy, Jamuna Vadivelu, Sylvia Daim, Soon-Hin How

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

    First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label,... Tekijä Yi‐Long Wu, Caicun Zhou, Chong Kin Liam, Gang Wu, X. Liu, Zhaoyang Zhong, Shun Lü, Ying Cheng, Baohui Han, Lin Chen, Cheng Huang, Shanshan Qin, Yixiang Zhu, Hui Pan, Houjie Liang, Elizabeth Li, Guangliang Jiang, Soon Hin How, Mitchel Fernando, Y. Zhang, Fan Xia, Yanchen Zuo

    Julkaistu 2015
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

    Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study Tekijä Gwo Fuang Ho, Chee-Shee Chai, Adlinda Alip, Mohd Ibrahim A. Wahid, Matin Mellor Abdullah, Y.C. Foo, Soon-Hin How, Adel Zaatar, Kai-Seng Lam, Kin-Wah Leong, John-Seng-Hooi Low, Mastura Md Yusof, Erica Chai-Yong Lee, Yok-Yong Toh, Chong Kin Liam

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

    Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 Tekijä Byoung Chul Cho, Myung‐Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih‐Hsin Yang, İrfan Çiçin, Dong‐Wan Kim, Yi‐Long Wu, Shun Lü, Ki Hyeong Lee, Yong‐Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zarić

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

    Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA Tekijä Se-Hoon Lee, Shun Lü, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Ki Hyeong Lee, Hailin Xiong, Soon Hin How, Ying Cheng, Gee‐Chen Chang, James C. Yang, Benjamin Besse, Michael Thomas, Sujay Shah, Mahadi Baig, Joshua C. Curtin, Jiarui Zhang, John Xie, Tao Sun, Seema Sethi, Miao Wang, E. Fennema, M. Daksh, Mariah Ennis, Joshua Bauml, Byoung Chul Cho

    Julkaistu 2025
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: